LAVA Therapeutics Investor Relations Material
Latest events
Q2 2025
13 Aug, 2025
Q1 2025
13 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from LAVA Therapeutics N.V.
Access all reports
LAVA Therapeutics N.V. is a biotechnology company focused on developing bispecific gamma-delta T cell engagers (TCEs) for cancer treatment. The company’s proprietary Gammabody platform is designed to activate the immune system by targeting gamma-delta T cells to recognize and destroy tumor cells. LAVA Therapeutics is advancing a pipeline of investigational therapies for hematologic and solid tumors through clinical research and industry collaborations. The company is headquartered in Utrecht, Netherlands, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
LVTX
Country
🇺🇸 United States